pharmaphorum | News & views on pharma and biotech’s evolving …
pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
2025 predictions and AI trends for pharma executives
4 days ago · JP Morgan Week 2025 - Fabrizio Chines. In this video from JPM 2025, pharmaphorum chats with SIFI CEO and Chairman Fabrizio Chines about a new treatment for acanthamoeba keratitis.
2025: The year ahead in pharma and life sciences | pharmaphorum
5 days ago · Discover the key trends and innovations shaping the pharma and life sciences industries in 2025, focusing on efficiency, patient care, customer experience, and advancements in rare disease treatments.
About pharmaphorum
3 days ago · pharmaphorum.com is a leading online destination for healthcare and pharmaceutical industry news, insight, and debate – as is its associated digital magazine Deep Dive. www.pharmaphorum.com
pharmaphorum - The Deep Dive Digital Magazine has fresh …
Feb 28, 2024 · Digital Health 2023. 29-11-2023 Deep Dive – Digital Health 2023 features interviews, analysis, and commentary from pharmaphorum, Lumanity, AXON, Viseven, Research Partnership, PurpleLeaf Strategy, M3, and more
Life Sciences Industry Report 2025 | pharmaphorum
Jan 9, 2025 · In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.
News | Timely industry updates for pharma and biotech leaders
pharmaphorum’s news coverage updates daily with the latest pharma and biotech stories, from funding and M&A to regulatory approvals and policy shifts.
The biopharma outlook for 2025: Opportunities and challenges
3 days ago · With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...
Deep Dive | A bimonthly magazine for in-depth pharma stories
pharmaphorum presents a bimonthly Deep Dive magazine with extended, visually appealing features on R&D, patients, market access, digital health, and more.
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal …
Nov 6, 2024 · Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...